Natural History of Cardiac Rhythm and Conduction Disorders in Patients With Fabry Disease Evaluated by Long-Term Implantable Holter ECG
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Occurrence of cardiac arrhythmias and conduction disorders
研究概览
简要总结
The main objective is to assess the occurrence of cardiac arrhythmias and conduction disorders during a three-year follow-up using implantable Holter ECG monitoring in 40 patients with Fabry disease. The secondary objectives are to analyze the correlations of these anomalies with changes in cardiac MRI and echocardiographic parameters as biological parameters and overall severity of the disease assessed by MSSI.
详细描述
The main objective of this non-blinded, monocentric non-randomized study is to assess the occurrence of cardiac arrhythmias and conduction disorders (sinus dysfunction, branch block [BB], atrioventricular block [BAV], sustained [TVS] or non-supported [TVNS] ventricular tachycardias, atrial fibrillation [AF] during a three-year follow-up in 40 patients with Fabry disease (half with left ventricular hypertrophy) using an implantable Holter ECG device (Medtronic Reveal-LINQ™). The secondary objectives are to analyze the correlations (at 1, 2 and 3 years) of these anomalies with the modifications of :
- cardiac MRI [Magnetic Resonance Imaging] data at inclusion [M0] and at 36 months [M36] (left ventricular hypertrophy [HVG], amplitude of the T1 signal, extent of fibrosis); MRIs will be performed before implantation and after removal of the Holter to avoid the reading artifacts linked to the device.
- echocardiographic measurements of the left ventricle (overall longitudinal strain systolic [SGL] and ejection fraction [FE])
- biological parameters (BNP or NT-proBNP, ultra-sensitive troponin and Lyso-Gb3)
- the overall severity of the disease assessed by MSSI (Mainz Severity Score Index), DFG and proteinuria
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Male patient
- •Age greater than or equal to 18 years on the day of inclusion
- •Presence of a morbid mutation for MF
- •Signature of the informed consent form
- •Absence of significant valve disease, verified on medical file (absence stenosis or regurgitation <2+ in color Doppler on a scale 1 to 4+ by extension of the jet)
- •No history of known or documented myocardial infarction nor CAD
- •No pacemaker or ICD
- •no history of AF, NSVT, high-degree AV block
- •Correct echogenicity
- •No treatment by corticosteroid or immunosuppressive drugs
- •creatinine clearance >/= 30 Ml/mn
- •LVEF ≥ 50% by ultrasound and / or MRI
- •No contraindication to MRI (or claustrophobia) and gadolinium injection
- •Affiliation to the French social security insurance
排除标准
- 未提供
研究组 & 干预措施
ONE
One single group of patients
干预措施: Implantation (subcutaneous) of a marketed miniaturized Holter ECG recording device (Diagnostic Test)
结局指标
主要结局
Occurrence of cardiac arrhythmias and conduction disorders
时间窗: 3 years
次要结局
- Correlations between electrical disorders and changes in MRI/ultrasonic data (LV mass, T1 signal, fibrosis extent , systolic strain, ejection fraction), concentrations of BNP, troponin, Lyso-Gb3, MSSI score and renal function(3 years)